Research
Neurodegenerative diseases
Free radical biomarkers help detect early neuroinflammation and oxidative stress, critical in diseases like Alzheimer’s and Parkinson’s before clinical symptoms manifest.
Proof points
Mitochondrial ROS monitoring:
Neurons under stress showed increased free radical production. Enables early drug evaluation in mitochondrial-targeted therapies.
Subcellular ROS sensing:
Free radical changes were observed in glial and neuronal compartments. Provides new tools for tracking neuroinflammation in real time.
Butyrate differentiation analog:
A reduction in oxidative stress was linked to phenotypic reprogramming. Suggests potential for tracking neuroprotective responses.
Advantages & complementarity
- Detects pre-symptomatic oxidative stress
- Complements imaging and cognitive tests
- Non-invasive monitoring of neuroinflammation
- High resolution in neurons and glia
- Tracks neuroprotective drug effectiveness
Partnership opportunities
We are eager to collaborate with neurology teams, academic centers, and biotech firms studying ALS, Parkinson’s, Alzheimer’s, and related disorders. Our biomarker can aid in tracking neuroprotective effects, mitochondrial drug engagement, and patient stratification in early-phase trials.
Share this:
